【US Stock Movement】Faeth Therapeutics surges on October 27: PIKTOR preclinical data + board expansion

Faeth Therapeutics October 27th Major Surge Analysis

Keywords: PIKTOR preclinical data, board member expansion

1. On October 23rd, the company released ESMO preclinical data: In two breast cancer xenograft models, oral PIKTOR inhibited tumor growth as effectively as or better than intravenous trastuzumab; when combined with fulvestrant or palbociclib, it achieved complete inhibition of tumor growth. The company stated that topline data from the PIK-201 endometrial cancer phase II trial is expected to be released before the end of 2026.

2. On October 27th, the company announced the appointment of Adam Schayowitz as a board member; he is currently Executive Vice President and Head of R&D at Zymeworks, with nearly 20 years of experience in oncology drug development and has led dozens of global development programs and several registration projects. The company’s main candidate project, PIKTOR, is being developed for endometrial cancer and breast cancer.

(Disclaimer: This content is summarized and generated by AI technology from publicly available information and is for reference only. It does not constitute investment advice.)